455 results on '"Poloni, Antonella"'
Search Results
2. Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report
3. Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms
4. Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study
5. A 50 Hz magnetic field influences the viability of breast cancer cells 96 h after exposure
6. MiR-422a promotes adipogenesis via MeCP2 downregulation in human bone marrow mesenchymal stem cells
7. Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience
8. Unveiling the genetic landscape of suspected congenital dyserythropoietic anemia type I: A retrospective cohort study of 36 patients
9. Bone Marrow Adipose Tissue
10. Uncommon Presentation of Sarcoidosis with Severe Thrombocytopenia and Hemorrhagic Diathesis
11. History and Scientific Production of Clinica Medica and Clinica Ematologica in Ancona
12. Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway
13. The Time Has Come for Targeted Therapies for AML: Lights and Shadows
14. Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment
15. Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations
16. AL amyloidosis: an overview on diagnosis, staging system, and treatment.
17. Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
18. Ataluren improves myelopoiesis and neutrophil chemotaxis by restoring ribosome biogenesis and reducing p53 levels in Shwachman–Diamond syndrome cells
19. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
20. Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study
21. Prescription patterns of venetoclax in acute myeloid leukemia.
22. S298: MATERNAL AND FETAL OUTCOMES IN PREGNANCIES OF WOMEN WITH IMMUNE THROMBOCYTOPENIA: A MULTICENTER RETROSPECTIVE OBSERVATIONAL ITP-NET ITALIAN STUDY
23. S173: RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY
24. PB2611: EVANS SYNDROME: DISEASE AWARENESS AND CLINICAL MANAGEMENT IN A NATION-WIDE ITALIAN SURVEY
25. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
26. Bone marrow adipose tissue is a unique adipose subtype with distinct roles in glucose homeostasis
27. Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study
28. Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights.
29. Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
30. Ataluren improves myelopoiesis and neutrophil chemotaxis by restoring ribosome biogenesis and reducing p53 levels in Shwachman–Diamond syndrome cells.
31. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
32. Molecular and Functional Characterization of Human Adipocytes
33. The Time Has Come for Targeted Therapies for AML: Lights and Shadows
34. Mutations in the splicing factor SF3B1are linked to frequent emergence of HLA-DRlow/negmonocytes in lower-risk myelodysplastic neoplasms
35. Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment.
36. A rare case of aCML associated with CNS involvement and with aggressive clinical course
37. Interaction between human mature adipocytes and lymphocytes induces T-cell proliferation
38. Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
39. A 50 Hz magnetic field influences the viability of breast cancer cells 96 h after exposure
40. Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry: An Italian Center Experience
41. Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine
42. Mobilization-Driven Postconsolidation Therapy in Elderly Patients with Acute Myeloid Leukemia: Feasibility and Efficacy of Autologous Stem Cell Transplantation versus Low-Dose Gemtuzumab Ozogamicin
43. PB2670: EQOL‐MDS TRIAL: PATIENT‐REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.
44. Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
45. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD
46. Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome
47. ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems
48. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia
49. Glial-Like Differentiation Potential of Human Mature Adipocytes
50. Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.